FDA Grants Priority Review to Intellia's Lonvo-z, an In Vivo CRISPR Therapy for Hereditary Angioedema
核心洞察
The FDA accepted Intellia Therapeutics' Biologics License Application for lonvoguran ziclumeran (搜索) (lonvo-z) in hereditary angioedema (搜索) and granted Priority Review with a PDUFA date of March 10, 2027.
The application is supported by global Phase 3 HAELO data showing an 87% reduction in mean monthly attacks versus placebo over the six-month efficacy evaluation period.
The FDA has indicated it does not currently plan to convene an advisory committee, and Intellia aims to launch lonvo-z commercially in the first half of 2027 if approved.
The U.S. Food and Drug Administration has accepted Intellia Therapeutics' Biologics License Application (BLA) for lonvoguran ziclumeran (搜索) (lonvo-z; formerly NTLA-2002) for the treatment of hereditary angioedema (搜索) (HAE) and granted the filing Priority Review, with a PDUFA target action date of March 10, 2027. The agency also informed Intellia that it does not currently plan to convene an advisory committee to discuss the BLA, a streamlined review path for what could become the world's first in vivo CRISPR-based therapy and the only one-time treatment for HAE if approved.
The submission, initiated as a rolling BLA in April 2026, is based on positive data from the global Phase 3 HAELO study. According to the company, HAELO met its primary endpoint and all key secondary endpoints, with a one-time infusion of lonvo-z reducing attacks by 87% compared with placebo over the six-month efficacy evaluation period. A majority of treated patients remained attack-free and free of HAE therapy over six months, and only mild to moderate adverse events were reported. Intellia reported additional positive data from HAELO in June 2026, which the company said further highlighted lonvo-z's potential to deliver meaningful disease control for HAE patients.
A One-Time Gene-Editing Approach to a Rare Genetic Disorder
HAE is a rare genetic disorder characterized by recurrent, potentially life-threatening swelling caused by excess bradykinin. Current management of the condition relies on lifelong, frequently administered prophylactic regimens, according to the source materials. Lonvo-z is designed as a single outpatient gene-editing intervention, and Intellia has stated that approval could significantly reshape the HAE treatment landscape by shifting patients away from chronic prophylaxis toward one-time therapy.
The company plans to commercially launch lonvo-z in the first half of 2027, contingent on potential approval in the United States.
Broader CRISPR Pipeline and Partnered Program
Beyond lonvo-z, Intellia's other lead candidate is nexiguran ziclumeran (nex-z; formerly NTLA-2001), a CRISPR-based gene-edited therapy being developed in collaboration with Regeneron Pharmaceuticals. Intellia is the lead party in the collaboration, with Regeneron sharing 25% of development costs and commercial profits.
Nex-z is being evaluated in two late-stage studies: MAGNITUDE in ATTR amyloidosis with cardiomyopathy (搜索) (ATTR-CM) and MAGNITUDE-2 in ATTR amyloidosis with polyneuropathy (搜索) (ATTRv-PN). Positive data from these studies would likely enable global regulatory filings for nex-z, according to the source materials.
Market Reaction
Year to date, shares of Intellia have rallied 41.7%, compared with an 11.2% increase for the industry, as reported by Zacks Investment Research. Intellia currently carries a Zacks Rank #3 (Hold).